Filing Flows › Comparisons › VXRT vs EDIT
Vaxart vs Editas Medicine: VXRT and EDIT compared
Vaxart is the larger company: $10.6M of revenue in its latest quarter (Q3 2026) against $10.4M for Editas Medicine (Q3 2026). Editas Medicine is growing faster (+37% against -85% a year earlier). Vaxart is more profitable, with an operating margin of -162.7% against -234.3%.
Where the money goes: VXRT and EDIT
Vaxart (VXRT) · Q3 2026
Vaxart, Q3 2026: revenue $10.6M (-85% year over year), operating margin -162.7%, net loss $17.7M, operating cash flow $1.4M. The chart follows the revenue to costs, profit and cash.
Editas Medicine (EDIT) · Q3 2026
Editas Medicine, Q3 2026: revenue $10.4M (+37% year over year), operating margin -234.3%, net loss $23.4M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
| Vaxart (VXRT) | Editas Medicine (EDIT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $10.6M | $10.4M |
| Revenue growth, Y/Y | -85% | +37% |
| Operating margin | -162.7% | -234.3% |
| Net earnings | −$17.7M | −$23.4M |
| Net margin | -166.6% | -225.7% |
| Operating cash flow | $1.4M | −$21.2M |
| Free cash flow | $1.1M | — |
Where the revenue comes from
Vaxart
- Government Contract: $7.5M (71%)
- Collaboration Revenue: $2.9M (28%)
- Non Cash Royalty Revenue: $154K (1%)
Questions
Which is bigger, Vaxart or Editas Medicine?
Vaxart is the larger company: $10.6M of revenue in its latest quarter (Q3 2026) against $10.4M for Editas Medicine (Q3 2026).
Is Vaxart or Editas Medicine growing faster?
Editas Medicine is growing faster (+37% against -85% a year earlier).
Which is more profitable, Vaxart or Editas Medicine?
Vaxart is more profitable, with an operating margin of -162.7% against -234.3%.
More: Vaxart earnings · how Vaxart makes money · Editas Medicine earnings · how Editas Medicine makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.